ABSTRACT: BACKGROUND AND PURPOSE Cannabis extracts and several cannabinoids have been shown to exert broad anti-inflammatory activities in experimental models of inflammatory CNS degenerative diseases. Clinical use of many cannabinoids is limited by their psychotropic effects. However, phytocannabinoids like cannabidiol (CBD), devoid of psychoactive activity, are, ... Continue Reading
multiple sclerosis
STUDY: Multiple Sclerosis – Systematic Review of Pharmacological Properties of the Oligodendrocyte Lineage
ABSTRACT: Oligodendrogenesis and oligodendrocyte precursor maturation are essential processes during the course of central nervous system development, and lead to the myelination of axons. Cells of the oligodendrocyte lineage are generated in the germinal zone from migratory bipolar oligodendrocyte precursor cells (OPCs), and acquire cell surface markers as they mature and ... Continue Reading
STUDY: Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis
ABSTRACT: This study investigated the antispasticity potential of Sativex in mice. Chronic relapsing experimental allergic encephalomyelitis was induced in adult ABH mice resulting in hind limb spasticity development. Vehicle, Sativex, and baclofen (as a positive control) were injected intravenously and the “stiffness” of limbs assessed by the resistance force against hind ... Continue Reading
STUDY: Sativex in the Management of Multiple Sclerosis-Related Spasticity: Role of the Corticospinal Modulation
ABSTRACT: Sativex is an emergent treatment option for spasticity in patients affected by multiple sclerosis (MS). This oromucosal spray, acting as a partial agonist at cannabinoid receptors, may modulate the balance between excitatory and inhibitory neurotransmitters, leading to muscle relaxation that is in turn responsible for spasticity improvement. Nevertheless, since the ... Continue Reading
STUDY: Regulators accused of bias against cannabis based medicines
ABSTRACT: A select committee of Britain's House of Lords this week accused the Medicines Control Agency of not dealing with cannabis based medicines in the same impartial manner as it dealt with other medicines. In its report it said that the agency's insistence that new toxicology data were needed on one of the 60 cannabinoids present in raw cannabis would delay the approval ... Continue Reading